SOURCE: Medical Care Technologies, Inc.

February 09, 2010 16:00 ET

Medical Care Technologies, Inc. Rolls Out Teledermatology Application

BEIJING--(Marketwire - February 9, 2010) - Medical Care Technologies Inc. (OTCBB: MDCE) today announced that as part of the wellness focus of Medical Care Technologies, the company is rolling out a Teledermatology application. Teledermatology is described as the practice of dermatology using available communication and information technology. Teledermatology is an important area of telemedicine activity that focuses primarily on the diagnosis and treatment of dermatologic conditions.

Medical Care Technologies Teledermatology incorporates both Store and Forward Teledermatology as well as live video teleconference Teledermatology. Live Video conferencing Teledermatology uses video and audio transmission for interactive consultation. Store and Forward Teledermatology incorporates clinical images and clinical information saved on MCT's Telehealth Suite™ and Medsuite™. In fact, the unique aspect of mobile Teledermatology is that this system might become a filtering or triage system allowing a more sensible approach for the management of patients with emergent skin diseases. In addition, mobile Teledermatology may also become a powerful screening tool for malignant cutaneous tumors.

The world dermatological market generated total sales revenues of over $18bn in 2007. VISIONGAIN predicts "that this market area will increase significantly, based on expansion of the market for modern drugs to treat skin disorders in developing and populated areas, most notably in countries like China and India."

Ning Wu, President of Medical Care Technologies, states, "China is on a path of rapid development. We believe that Chinese dermatology will continue its own parallel rapid progression and that Teledermatology consultation is well suited to our current applications, as well as being a much needed service in China."

About Medical Care Technologies Inc.

Medical Care Technologies Inc. ( is traded under the symbol MDCE on the OTCBB and is based in London, England. The Company is in the process of moving its portfolio of oil resources into medical care technologies. The products/services that the company hopes to acquire are intended to constitute a healthcare delivery and wellness site, dedicated to helping Asian consumers live healthier, more balanced lives. MDCE is planning to provide advanced connectivity, internationally standardized and secure business technology and information systems to assist the Asian health industry -- physicians, pharmacists, medical institutions, and consumers -- in accessing medical resources, health services, education, wellness and pharmaceutical products throughout Asia. MDCE is planning to distribute and provide services at a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Nutraceuticals. Further information on the Company can be found at and the company's website at

Safe Harbor Statement

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: MDCE's products, services, capabilities, performance, opportunities, development and business outlook, guidance on our future financial results and other projections or measures of our future performance; the amount and timing of the benefits expected from strategic initiatives and acquisitions or from deployment of new or updated technologies, products, services or applications; and other potential sources of additional revenue. These statements are based on our current plans and expectations and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: lack of operating history, transitioning from a development company to an operating company, difficulties in distinguishing MDCE's products and services, ability to deploy MDCE's services and products, market acceptance of our products and services; operational difficulties relating to combining acquired companies and businesses; our ability to form and maintain mutually beneficial relationships with customers and strategic partners; changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and healthcare and pharmaceutical industries, and our ability to attract and retain qualified personnel. Other risks and uncertainties may include, but are not limited to: lack of or delay in market acceptance and fluctuations in customer demand, dependence on a limited number of significant customers, reliance on third party vendors and strategic partners, ability to meet future capital requirements on acceptable terms, continuing uncertainty in the global economy, and compliance with federal and state regulatory requirement. Further information about these matters can be found in our Securities and Exchange Commission filings. We expressly disclaim any intent or obligation to update these forward-looking statements. There can be no assurance that the acquisition of GUC's assets will close. MDCE must issue 57,300,000 shares of its common stock to GUC, or GUC's designees in order to close the acquisition. Accounting for the anticipated cancellation of 57,300,000 shares by Patricia Traczykowski, MDCE will have 98,900,000 shares of its common stock issued and outstanding upon the closing of the acquisition.

Contact Information